170 related articles for article (PubMed ID: 36992402)
41. Clinical Management of Patients With B-Cell Depletion Agents to Treat or Prevent Prolonged and Severe SARS-COV-2 Infection: Defining a Treatment Pathway.
D'Abramo A; Vita S; Maffongelli G; Beccacece A; Agrati C; Cimini E; Colavita F; Giancola ML; Cavasio A; Nicastri E;
Front Immunol; 2022; 13():911339. PubMed ID: 35711444
[TBL] [Abstract][Full Text] [Related]
42. Analysis of adjunctive serological detection to nucleic acid test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection diagnosis.
Liu R; Liu X; Yuan L; Han H; Shereen MA; Zhen J; Niu Z; Li D; Liu F; Wu K; Luo Z; Zhu C
Int Immunopharmacol; 2020 Sep; 86():106746. PubMed ID: 32619956
[TBL] [Abstract][Full Text] [Related]
43. PROTECT Trial: A cluster-randomized study with hydroxychloroquine versus observational support for prevention or early-phase treatment of Coronavirus disease (COVID-19): A structured summary of a study protocol for a randomized controlled trial.
Nanni O; Viale P; Vertogen B; Lilli C; Zingaretti C; Donati C; Masini C; Monti M; Serra P; Vespignani R; Grossi V; Biggeri A; Scarpi E; Galardi F; Bertoni L; Colamartini A; Falcini F; Altini M; Massa I; Gaggeri R; Martinelli G
Trials; 2020 Jul; 21(1):689. PubMed ID: 32736597
[TBL] [Abstract][Full Text] [Related]
44. Longitudinal profile of immunoglobulin G (IgG), IgM, and IgA antibodies against the severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein in patients with pneumonia due to the SARS coronavirus.
Woo PC; Lau SK; Wong BH; Chan KH; Chu CM; Tsoi HW; Huang Y; Peiris JS; Yuen KY
Clin Diagn Lab Immunol; 2004 Jul; 11(4):665-8. PubMed ID: 15242938
[TBL] [Abstract][Full Text] [Related]
45. Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study.
Morschhauser F; Le Gouill S; Feugier P; Bailly S; Nicolas-Virelizier E; Bijou F; Salles GA; Tilly H; Fruchart C; Van Eygen K; Snauwaert S; Bonnet C; Haioun C; Thieblemont C; Bouabdallah R; Wu KL; Canioni D; Meignin V; Cartron G; Houot R
Lancet Haematol; 2019 Aug; 6(8):e429-e437. PubMed ID: 31296423
[TBL] [Abstract][Full Text] [Related]
46. Evaluation of anti-severe acute respiratory syndrome coronavirus 2 antibody levels in coronavirus disease breakthrough infection during immunosuppressive therapy in a patient with connective tissue disease-related interstitial lung disease.
Wada TT; Yokota K; Sakai S; Soma M; Kajiyama H; Tarumoto N; Maesaki S; Maeda T; Nagata M; Mimura T
Mod Rheumatol Case Rep; 2023 Jan; 7(1):288-292. PubMed ID: 35730997
[TBL] [Abstract][Full Text] [Related]
47. Anti-SARS-CoV-2 IgM/IgG antibodies detection using a patch sensor containing porous microneedles and a paper-based immunoassay.
Bao L; Park J; Qin B; Kim B
Sci Rep; 2022 Jul; 12(1):10693. PubMed ID: 35778408
[TBL] [Abstract][Full Text] [Related]
48. [Repurposing of chlorpromazine in COVID-19 treatment: the reCoVery study].
Plaze M; Attali D; Petit AC; Blatzer M; Simon-Loriere E; Vinckier F; Cachia A; Chrétien F; Gaillard R
Encephale; 2020 Jun; 46(3S):S35-S39. PubMed ID: 32387014
[TBL] [Abstract][Full Text] [Related]
49. Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) infection during late pregnancy: a report of 18 patients from Wuhan, China.
Zhang L; Dong L; Ming L; Wei M; Li J; Hu R; Yang J
BMC Pregnancy Childbirth; 2020 Jul; 20(1):394. PubMed ID: 32641013
[TBL] [Abstract][Full Text] [Related]
50. Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19.
Hueso T; Pouderoux C; Péré H; Beaumont AL; Raillon LA; Ader F; Chatenoud L; Eshagh D; Szwebel TA; Martinot M; Camou F; Crickx E; Michel M; Mahevas M; Boutboul D; Azoulay E; Joseph A; Hermine O; Rouzaud C; Faguer S; Petua P; Pommeret F; Clerc S; Planquette B; Merabet F; London J; Zeller V; Ghez D; Veyer D; Ouedrani A; Gallian P; Pacanowski J; Mékinian A; Garnier M; Pirenne F; Tiberghien P; Lacombe K
Blood; 2020 Nov; 136(20):2290-2295. PubMed ID: 32959052
[TBL] [Abstract][Full Text] [Related]
51. Successful Chimeric Antigen Receptor (CAR) T-Cell Treatment in Aggressive Lymphoma Despite Coronavirus Disease 2019 (CoVID-19) and Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Replication - Case Report.
Nilius-Eliliwi V; Mika T; Baraniskin A; Wünnenberg M; Maslova M; Boy C; Klein-Scory S; Schroers R; Vangala D
Front Oncol; 2021; 11():706431. PubMed ID: 34336692
[TBL] [Abstract][Full Text] [Related]
52. Reply to "successful early use of anti-SARS-CoV-2 monoclonal neutralizing antibodies in SARS-CoV-2 infected hematological patients-A Czech multicenter experience": A case series of SARS-CoV-2 Omicron infection and aggressive lymphoma in the Sotrovimab era.
Cassin R; Rampi N; C F; Muscatello A; Mariani B; Noto A; Rossi FG; Baldini L
Hematol Oncol; 2023 Feb; 41(1):213-217. PubMed ID: 36156809
[TBL] [Abstract][Full Text] [Related]
53. A Case of a Malignant Lymphoma Patient Persistently Infected with SARS-CoV-2 for More than 6 Months.
Nagasaki Y; Kadowaki M; Nakamura A; Etoh Y; Shimo M; Ishihara S; Arimizu Y; Iwamoto R; Kamamuta S; Iwasaki H
Medicina (Kaunas); 2023 Jan; 59(1):. PubMed ID: 36676732
[TBL] [Abstract][Full Text] [Related]
54. Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial.
Garcia-Vicuña R; Abad-Santos F; González-Alvaro I; Ramos-Lima F; Sanz JS
Trials; 2020 Sep; 21(1):772. PubMed ID: 32907638
[TBL] [Abstract][Full Text] [Related]
55. Prolonged shedding of SARS-CoV-2 in an elderly liver transplant patient infected by COVID-19: a case report.
Wei L; Liu B; Zhao Y; Chen Z
Ann Palliat Med; 2021 Jun; 10(6):7003-7007. PubMed ID: 33183020
[TBL] [Abstract][Full Text] [Related]
56. COVID-19 Pneumonia in Vaccinated Population: A Six Clinical and Radiological Case Series.
Brogna B; Bignardi E; Brogna C; Capasso C; Gagliardi G; Martino A; Musto LA
Medicina (Kaunas); 2021 Aug; 57(9):. PubMed ID: 34577814
[TBL] [Abstract][Full Text] [Related]
57. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.
Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J
Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494
[TBL] [Abstract][Full Text] [Related]
58. Successful Elimination of SARS-CoV-2 Following Vaccination with BNT162b2 after Prolonged Viral Infection in an Immunocompromised Lymphoma Patient.
Hagihara M; Imai Y; Uchida T; Ohara S; Inoue M; Sugi T; Mitamura K
Intern Med; 2022; 61(14):2215-2219. PubMed ID: 35850990
[TBL] [Abstract][Full Text] [Related]
59. COVID-19 and lombardy: TESTing the impact of the first wave of the pandemic.
Perico L; Tomasoni S; Peracchi T; Perna A; Pezzotta A; Remuzzi G; Benigni A
EBioMedicine; 2020 Nov; 61():103069. PubMed ID: 33130396
[TBL] [Abstract][Full Text] [Related]
60. Longitudinal Monitoring of SARS-CoV-2 IgM and IgG Seropositivity to Detect COVID-19.
Suhandynata RT; Hoffman MA; Kelner MJ; McLawhon RW; Reed SL; Fitzgerald RL
J Appl Lab Med; 2020 Sep; 5(5):908-920. PubMed ID: 32428207
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
